The most promising compound suggested by the modeling studies was experimentally validated and shown to block the activity of CD36 by decreasing the amounts of long chain fatty acids that could be taken up by AML cells, and additionally generating reduced AML cell viability. The gene discussed is CD36; the disease is acute myeloid leukemia.